×
About 32,237 results

ALLMedicine™ Lymphomas Center

Research & Reviews  15,415 results

Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic ...
https://doi.org/10.1038/s41375-021-01221-5 10.1146/annurev-immunol-020711-075027 10.1038/nri955 10.1084/jem.20040544 10.1046/j.1365-2141.2003.04679.x 10.1182/blood-2010-05-284984 10.1182/blood-2006-03-011759 10.1182/blood-2011-06-338855 10.1182/blood-2007-12-127688 10.1371/journal.pone.0060275 10.1182/blood-2006-09-045377 10.1093/intimm/12.4.517 10.1038/s41598-018-36853-8 10.1093/bioinformatics/btt705 10.1073/pnas.1211130110 10.1093/bioinformatics/btu638 10.1093/nar/gks042 10.1074/mcp.M113.031591 10.1093/bioinformatics/btt350 10.1093/bioinformatics/btu845 10.1074/mcp.M115.055897 10.1038/ni.1699 10.1016/j.cell.2011.02.015 10.1111/j.1467-9868.2010.00740.x 10.1016/j.cell.2011.03.007 10.1093/database/bau129 10.1074/mcp.M900415-MCP200 10.1371/journal.pone.0002097 10.1371/journal.pone.0043432 10.1038/nature10098 10.1371/journal.pone.0034515 10.1038/leu.2011.66 10.1182/blood-2004-10-3819 10.1172/JCI119849 10.1038/ni.1771 10.1093/emboj/18.23.6694 10.3390/cells8070646 10.1111/j.1365-2141.2005.05481.x 10.1371/journal.pone.0215746 10.1038/ncb2502 10.18632/oncotarget.13373 10.1158/0008-5472.CAN-06-3875 10.1073/pnas.1713462114 10.1046/j.1440-1711.2003.t01-1-01177.x 10.4049/jimmunol.1601609 10.1182/blood-2006-07-036210 10.1182/blood-2012-11-467670 10.1007/s00277-013-1846-6 10.1182/blood.V99.1.232 10.1182/blood.V94.6.1840 10.1002/cyto.b.20132
Leukemia Schleiss C, Carapito R et. al.

Apr 9th, 2021 - B-cell receptor (BCR) signaling is crucial for the pathophysiology of most mature B-cell lymphomas/leukemias and has emerged as a therapeutic target whose effectiveness remains limited by the occurrence of mutations. Therefore, deciphering the cel...

H. pylori negative gastric MALT lymphoma with API2-MALT1 translocation treated by endos...
https://doi.org/10.1097/MD.0000000000024371
Medicine Tahara T, Horiguchi N et. al.

Apr 9th, 2021 - API2-MALT1 positive gastric mucosa-associated lymphoid tissue (MALT) lymphomas are considered to have favorable prognosis. We report a case of API2-MALT1 positive gastric MALT lymphoma, treated by endoscopic submucosal dissection (ESD). A 51-year-...

Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for mol...
https://doi.org/10.1111/ijd.15451
International Journal of Dermatology; Rendón-Serna N, Correa-Londoño LA et. al.

Apr 9th, 2021 - Cutaneous T-cell lymphomas (CTCL) result from the infiltration and proliferation of a population of T cells in the skin, inducing changes in the activity of both T cells and surrounding skin cells. In the CTCL microenvironment, cell interactions m...

Gastrointestinal Tract Lymphomas: A Review of the Most Commonly Encountered Lymphomas.
https://doi.org/10.5858/arpa.2020-0661-RA
Archives of Pathology & Laboratory Medicine; Alvarez-Lesmes J, Chapman JR et. al.

Apr 9th, 2021 - The gastrointestinal (GI) tract is the most common site of extranodal non-Hodgkin lymphoma, accounting for 20% to 40% of all extranodal lymphomas. The majority of these are systemic processes secondarily involving the GI tract. Primary GI lymphoma...

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
https://doi.org/10.1182/blood.2020010497
Blood Chihara D, Dores G et. al.

Apr 6th, 2021 - Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCL; TCL) specifically are less well understood. We used pop...

see more →

Guidelines  87 results

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas

May 29th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. T...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 8th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
https://www.sciencedirect.com/science/article/pii/S0923753419354651
Annals of Oncology; Zucca E,et al

Dec 31st, 2019 - This updated ESMO Clinical Practice Guideline provides key recommendations on the management of marginal zone lymphomas.

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommenda...

see more →

Drugs  83 results see all →

Clinicaltrials.gov  16,007 results

Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic ...
https://doi.org/10.1038/s41375-021-01221-5 10.1146/annurev-immunol-020711-075027 10.1038/nri955 10.1084/jem.20040544 10.1046/j.1365-2141.2003.04679.x 10.1182/blood-2010-05-284984 10.1182/blood-2006-03-011759 10.1182/blood-2011-06-338855 10.1182/blood-2007-12-127688 10.1371/journal.pone.0060275 10.1182/blood-2006-09-045377 10.1093/intimm/12.4.517 10.1038/s41598-018-36853-8 10.1093/bioinformatics/btt705 10.1073/pnas.1211130110 10.1093/bioinformatics/btu638 10.1093/nar/gks042 10.1074/mcp.M113.031591 10.1093/bioinformatics/btt350 10.1093/bioinformatics/btu845 10.1074/mcp.M115.055897 10.1038/ni.1699 10.1016/j.cell.2011.02.015 10.1111/j.1467-9868.2010.00740.x 10.1016/j.cell.2011.03.007 10.1093/database/bau129 10.1074/mcp.M900415-MCP200 10.1371/journal.pone.0002097 10.1371/journal.pone.0043432 10.1038/nature10098 10.1371/journal.pone.0034515 10.1038/leu.2011.66 10.1182/blood-2004-10-3819 10.1172/JCI119849 10.1038/ni.1771 10.1093/emboj/18.23.6694 10.3390/cells8070646 10.1111/j.1365-2141.2005.05481.x 10.1371/journal.pone.0215746 10.1038/ncb2502 10.18632/oncotarget.13373 10.1158/0008-5472.CAN-06-3875 10.1073/pnas.1713462114 10.1046/j.1440-1711.2003.t01-1-01177.x 10.4049/jimmunol.1601609 10.1182/blood-2006-07-036210 10.1182/blood-2012-11-467670 10.1007/s00277-013-1846-6 10.1182/blood.V99.1.232 10.1182/blood.V94.6.1840 10.1002/cyto.b.20132
Leukemia Schleiss C, Carapito R et. al.

Apr 9th, 2021 - B-cell receptor (BCR) signaling is crucial for the pathophysiology of most mature B-cell lymphomas/leukemias and has emerged as a therapeutic target whose effectiveness remains limited by the occurrence of mutations. Therefore, deciphering the cel...

H. pylori negative gastric MALT lymphoma with API2-MALT1 translocation treated by endos...
https://doi.org/10.1097/MD.0000000000024371
Medicine Tahara T, Horiguchi N et. al.

Apr 9th, 2021 - API2-MALT1 positive gastric mucosa-associated lymphoid tissue (MALT) lymphomas are considered to have favorable prognosis. We report a case of API2-MALT1 positive gastric MALT lymphoma, treated by endoscopic submucosal dissection (ESD). A 51-year-...

Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for mol...
https://doi.org/10.1111/ijd.15451
International Journal of Dermatology; Rendón-Serna N, Correa-Londoño LA et. al.

Apr 9th, 2021 - Cutaneous T-cell lymphomas (CTCL) result from the infiltration and proliferation of a population of T cells in the skin, inducing changes in the activity of both T cells and surrounding skin cells. In the CTCL microenvironment, cell interactions m...

Gastrointestinal Tract Lymphomas: A Review of the Most Commonly Encountered Lymphomas.
https://doi.org/10.5858/arpa.2020-0661-RA
Archives of Pathology & Laboratory Medicine; Alvarez-Lesmes J, Chapman JR et. al.

Apr 9th, 2021 - The gastrointestinal (GI) tract is the most common site of extranodal non-Hodgkin lymphoma, accounting for 20% to 40% of all extranodal lymphomas. The majority of these are systemic processes secondarily involving the GI tract. Primary GI lymphoma...

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
https://doi.org/10.1182/blood.2020010497
Blood Chihara D, Dores G et. al.

Apr 6th, 2021 - Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCL; TCL) specifically are less well understood. We used pop...

see more →

News  641 results

CAR T-cell Products Shine in Real-World Setting, Reveal New Insights
https://www.medscape.com/viewarticle/946240

Feb 21st, 2021 - Real-world experience with chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas compares favorably with experience in commercial and trial settings and provides new insights for predicting outcomes, according to Paolo Corrad...

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
https://www.medscape.com/viewarticle/945426

Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...

FDA OKs New CAR T- Cell Tx for Large B-cell Lymphomas
https://www.medscape.com/viewarticle/945417

Feb 4th, 2021 - The US Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi), a chimeric antigen receptor (CAR) T-cell product for the treatment of adults with certain types of relapsed or refractory large B-cell lymphoma who relapse...

Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas
https://www.medscape.com/viewarticle/942195

Dec 7th, 2020 - In patients with T-cell lymphoma, allogeneic transplant can lead to durable remissions among patients who might otherwise have poor outcomes, results of a large retrospective observational study suggest. Five-year progression-free survival (PFS) a...

Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers
https://www.medscape.com/viewarticle/941593

Nov 24th, 2020 - Risk factors for keratinocyte carcinomas, primarily pigment traits and sun sensitivity, were associated with the risk of developing non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL) in an analysis of 92,097 women in France. The pr...

see more →

Patient Education  4 results see all →